Mao Lin

914 total citations
27 papers, 762 citations indexed

About

Mao Lin is a scholar working on Oncology, Immunology and Biotechnology. According to data from OpenAlex, Mao Lin has authored 27 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Immunology and 10 papers in Biotechnology. Recurrent topics in Mao Lin's work include Cancer Immunotherapy and Biomarkers (9 papers), Microbial Inactivation Methods (9 papers) and Immune Cell Function and Interaction (8 papers). Mao Lin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Microbial Inactivation Methods (9 papers) and Immune Cell Function and Interaction (8 papers). Mao Lin collaborates with scholars based in China and United States. Mao Lin's co-authors include Jibing Chen, Shuzhen Liang, Kecheng Xu, Lizhi Niu, Lizhi Niu, Mingjie Zhang, Yong Jiang, Haihua Luo, Mohammed Alnaggar and Yingqing Liang and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Allergy and Clinical Immunology and Frontiers in Immunology.

In The Last Decade

Mao Lin

27 papers receiving 739 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mao Lin China 17 536 467 118 102 84 27 762
Brian M. Olson United States 9 321 0.6× 308 0.7× 28 0.2× 95 0.9× 167 2.0× 27 590
Laura McOlash United States 13 426 0.8× 263 0.6× 34 0.3× 50 0.5× 123 1.5× 15 661
Mengmeng Lü China 11 328 0.6× 207 0.4× 51 0.4× 59 0.6× 115 1.4× 15 447
Hidetoshi Nakagawa Japan 17 419 0.8× 529 1.1× 21 0.2× 39 0.4× 145 1.7× 35 853
Fumitaka Arihara Japan 7 327 0.6× 319 0.7× 20 0.2× 95 0.9× 50 0.6× 13 555
Joanne Chin‐Aleong United Kingdom 12 581 1.1× 402 0.9× 25 0.2× 43 0.4× 201 2.4× 18 963
Cathy Biota France 8 628 1.2× 776 1.7× 16 0.1× 63 0.6× 115 1.4× 9 982
Guoxiu Du China 6 397 0.7× 233 0.5× 17 0.1× 52 0.5× 131 1.6× 6 516
Qiu‐Xia Qu China 13 474 0.9× 466 1.0× 19 0.2× 104 1.0× 142 1.7× 33 734

Countries citing papers authored by Mao Lin

Since Specialization
Citations

This map shows the geographic impact of Mao Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mao Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mao Lin more than expected).

Fields of papers citing papers by Mao Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mao Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mao Lin. The network helps show where Mao Lin may publish in the future.

Co-authorship network of co-authors of Mao Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Mao Lin. A scholar is included among the top collaborators of Mao Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mao Lin. Mao Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xing, Yanli, Hongmei Li, Bing Liang, et al.. (2022). Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Journal of Oncology. 2022. 1–12. 3 indexed citations
2.
Liu, Shupeng, Bing Liang, Yanhong Li, et al.. (2022). CT-Guided Percutaneous Cryoablation in Patients with Lung Nodules Mainly Composed of Ground-Glass Opacities. Journal of Vascular and Interventional Radiology. 33(8). 942–948. 10 indexed citations
3.
Lin, Mao, et al.. (2022). Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy. Frontiers in Immunology. 13. 1038715–1038715. 13 indexed citations
4.
Yu, Jie, Hui Ji, Xiaosong Tang, et al.. (2021). Chemotherapy plus concurrent irreversible electroporation improved local tumor control in unresectable hilar cholangiocarcinoma compared with chemotherapy alone. International Journal of Hyperthermia. 38(1). 1512–1518. 6 indexed citations
5.
Lin, Mao, Haihua Luo, Shuzhen Liang, et al.. (2020). Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients. Journal of Clinical Investigation. 130(5). 2560–2569. 109 indexed citations
6.
Lin, Mao, Xiaoyan Zhang, Shuzhen Liang, et al.. (2020). Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduction and Targeted Therapy. 5(1). 215–215. 75 indexed citations
7.
Alnaggar, Mohammed, Mao Lin, Shuzhen Liang, et al.. (2018). Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome. Cellular Physiology and Biochemistry. 48(5). 1882–1893. 59 indexed citations
8.
Lin, Mao, Mohammed Alnaggar, Shuzhen Liang, et al.. (2018). Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer. Cellular Physiology and Biochemistry. 47(4). 1556–1564. 21 indexed citations
9.
10.
Lin, Mao, Shuzhen Liang, Xiaohua Wang, et al.. (2017). Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. Journal of Cancer Research and Clinical Oncology. 143(12). 2607–2618. 46 indexed citations
11.
Lin, Mao, Kecheng Xu, Shuzhen Liang, et al.. (2017). Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer. Immunology Letters. 184. 98–104. 32 indexed citations
12.
Lin, Mao, Shuzhen Liang, Jian Shi, et al.. (2017). Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer. Immunology Letters. 191. 10–15. 36 indexed citations
13.
Lin, Mao, Mohammed Alnaggar, Shuzhen Liang, et al.. (2017). Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer. Immunologic Research. 66(1). 172–178. 3 indexed citations
14.
Lin, Mao, Shuzhen Liang, Xiaohua Wang, et al.. (2017). Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunologic Research. 65(4). 880–887. 59 indexed citations
15.
Lin, Mao, Shuzhen Liang, Xiao Hua Wang, et al.. (2017). Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. Immunology Letters. 186. 20–27. 36 indexed citations
16.
Liang, Shuzhen, Lizhi Niu, Kecheng Xu, et al.. (2017). Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer. Molecular Immunology. 92. 45–53. 31 indexed citations
17.
Shi, Jian, Yuan Li, Shuzhen Liang, et al.. (2016). Circulating tumour cells as biomarkers for evaluating cryosurgery on unresectable hepatocellular carcinoma. Oncology Reports. 36(4). 1845–1851. 16 indexed citations
18.
Lin, Mao, et al.. (2015). Safety and efficacy study of lung cancer stem cell vaccine. Immunologic Research. 62(1). 16–22. 10 indexed citations
19.
Lin, Mao, et al.. (2015). Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. Journal of Cancer Research and Clinical Oncology. 141(10). 1827–1833. 23 indexed citations
20.
Lin, Mao, Shupeng Liu, Lizhi Niu, et al.. (2015). Safety and efficacy study of nasopharyngeal cancer stem cell vaccine. Immunology Letters. 165(1). 26–31. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian M. Olson Breakdown of academic impact, for papers by Laura McOlash Breakdown of academic impact, for papers by Mengmeng Lü Breakdown of academic impact, for papers by Hidetoshi Nakagawa Breakdown of academic impact, for papers by Fumitaka Arihara Breakdown of academic impact, for papers by Joanne Chin‐Aleong Breakdown of academic impact, for papers by Cathy Biota Breakdown of academic impact, for papers by Guoxiu Du Breakdown of academic impact, for papers by Qiu‐Xia Qu
Rankless by CCL
2026